Last reviewed · How we verify

Post-operative Ondansetron anti-emesis

James Cook University Hospital · Phase 1 active Small molecule Quality 10/100

Post-operative Ondansetron anti-emesis is a Small molecule drug developed by James Cook University Hospital. It is currently in Phase 1 development.

At a glance

Generic namePost-operative Ondansetron anti-emesis
SponsorJames Cook University Hospital
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Post-operative Ondansetron anti-emesis

What is Post-operative Ondansetron anti-emesis?

Post-operative Ondansetron anti-emesis is a Small molecule drug developed by James Cook University Hospital.

Who makes Post-operative Ondansetron anti-emesis?

Post-operative Ondansetron anti-emesis is developed by James Cook University Hospital (see full James Cook University Hospital pipeline at /company/james-cook-university-hospital).

What development phase is Post-operative Ondansetron anti-emesis in?

Post-operative Ondansetron anti-emesis is in Phase 1.

What are the side effects of Post-operative Ondansetron anti-emesis?

Common side effects of Post-operative Ondansetron anti-emesis include Muscle weakness upper limb [left], Numbness in left arm, Paresthesia [left], Hematoma, Muscle weakness upper limb [right], Numbness in right arm.

Related